Drug Trial Radar · NCT05060705
"Efesovir" (FS-1) for COVID-19, Phase 2
Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
Dec 2025
Primary completion
Apr 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Scientific Center for Anti-infectious Drugs, KazakhstanIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug "Remdesivir" in the treatment of patients hospitalized with COVID-19. The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to 30% higher than of "Remdesivir".
Conditions
- Covid19
Interventions
EfesovirDrug
Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response RateTime frame: 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Semey Medical University
Semey, East Kazakhstan, Kazakhstan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.